Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting (NEXST)

Bayer

Status: Completed

Conditions: Carcinoma, Renal Cell

Treatments: Drug: Sorafenib (Nexavar, BAY43-9006)

Study type: Observational

Funder types: Industry

Identifiers

NCT01557127

16268

Details and patient eligibility

About

This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.

Enrollment: 205 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >/= 18 years
• Diagnosis of renal cell carcinoma
• Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or disqualified from therapy with IFN/IL-2
• Patients in whom the oncologist has decide to start therapy with sorafenib.

Exclusion criteria

• Synonymous with contraindications to Nexavar.

Trial design

205 participants in 1 patient group

Group 1

Treatment:

Drug: Sorafenib (Nexavar, BAY43-9006)